Prostate Cancer Oral and Intravenous Drug Coverage Criteria
Customize your policy alerts
Sign up for all Premera Bluecross policy alerts
Know when Premera Bluecross releases new policies or updates existing guidance.
Monitor payer policy activity
Coverage and prior authorization criteria for selected oral and intravenous medications used to treat advanced prostate cancer, including drug-specific indications, combination therapy, prior treatment, step therapy, site of care, and continuation requirements.
Added coverage criteria for Abirtega, generic abiraterone, and Zytiga in combination with capivasertib.
Added coverage for Akeega in BRCA2-mutated metastatic castration-sensitive prostate cancer.
Changed the initial authorization period for listed oral drugs from 3 months to 6 months.
Added an androgen deprivation therapy requirement for specified abiraterone, darolutamide, and apalutamide products.
Removed the step requirement for Zytiga before Xtandi.
Added and expanded coverage criteria for Yonsa, Nubeqa, and Erleada.
Added new indications and NCCN recommendations for Xtandi.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.